We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Non-Invasive Gut Tests Could Help Diagnose Inflammatory Bowel Disease and Colon Cancer

By LabMedica International staff writers
Posted on 15 Feb 2024

New research is set to simplify and make gut health monitoring less invasive by focusing on an often-ignored yet readily available source: the mucus in our digestive tract that ultimately becomes part of fecal matter. More...

Researchers at UBC Okanagan (Kelowna, BC, Canada) have developed a method to analyze vital gut health markers from fecal-adherent mucus, essentially the mucus that adheres to stool. This mucus, typically discarded in stool, is actually rich in data about gut health. The team has pioneered a non-invasive approach to study MUC2, a key protein found in the stool that plays a significant role in gut health. MUC2 is a glycoprotein with numerous sugar chains that creates a protective mucus barrier in the intestines. This barrier is essential for defending the gut against harmful microbes and toxins and is integral to digestive health.

Previously, it was believed that this crucial molecule could only be extracted through invasive and painful methods like biopsies or surgical tissue removal. However, this study has revealed that mucus is a natural component of human stool, meaning it can be painlessly obtained and at levels not possible before at any time and that too non-invasively. A deeper understanding of MUC2 could pave the way for breakthroughs in the treatment and prevention of gut-related diseases, potentially improving the daily health of millions.

“MUC2 is like the silent star in our guts. It’s constantly working to protect us, and its proper functioning is crucial for our overall health,” said researcher Dr. Kirk Bergstrom. “We can use these new methods to visualize mucus-microbiota interactions and how they go wrong in various diseases, like inflammatory bowel diseases and colon cancer.”

Related Links:
UBC Okanagan


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The Volition Nu.Q nucleosome assay runs on the IDS i10 automated analyzer platform (Photo courtesy of VolitionRx)

Groundbreaking Lateral Flow Test Quantifies Nucleosomes in Whole Venous Blood in Minutes

Diagnosing immune disruptions quickly and accurately is crucial in conditions such as sepsis, where timely intervention is critical for patient survival. Traditional testing methods can be slow, expensive,... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.